FDA Approves Supplemental NDA for Argatroban by Fresenius Kabi
The FDA has approved a supplemental NDA for Argatroban submitted by Fresenius Kabi.
Published: July 16, 2026
Updated: July 16, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Anticoagulant
Asset: Argatroban
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Argatroban
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of a supplemental NDA for Argatroban by Fresenius Kabi is significant as it strengthens their competitive position in the anticoagulant market. Portfolio teams should evaluate how this approval may influence market dynamics and their own product strategies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for any additional indications or formulations that may be pursued by Fresenius Kabi for Argatroban.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.